&w=3840&q=100)
India's oil intake has tripled-how much is too much for your health?
India's per capita oil intake has jumped to 23.5 kg a year-nearly twice the ICMR's limit-raising health concerns over obesity, heart disease, and diabetes
New Delhi
India's edible oil consumption has tripled in the past 20 years, rising from 8.2 kg per capita in 2001 to 23.5 kg today, according to a recent report. This is nearly double the upper limit recommended by the Indian Council of Medical Research (ICMR). While fats are essential, health experts warn that uncontrolled oil intake—especially from refined and processed sources—is quietly fuelling a national health crisis.
'We often forget that oil, though essential, is extremely calorie-dense. Just one tablespoon adds over 100 calories. It's not only about what oil we use, but also how much we consume without realising,' says Dr Charu Dua, Chief Dietician and Head of Clinical Nutrition at Amrita Institute of Medical Sciences and former Chief Clinical Nutritionist at Max Super Speciality Hospital, Patparganj.
How much cooking oil is too much per day?
According to the World Health Organization (WHO), total fat should account for only 15–30 per cent of daily caloric intake, with unsaturated fats forming the bulk. For an average 2,000-calorie diet, this means no more than 30 grams of total fat per day, including oils.
The ICMR's guidelines advise:
20–50 grams of visible fats per day, depending on activity levels
27–30 grams per day for an average adult with a 2,000 kcal requirement
'Most urban diets far exceed this. The oil in curries, fried snacks, or even restaurant food adds up quickly. What we forget to count is the invisible oil—in biscuits, snacks, and packaged food,' Dr Dua points out.
Which cooking oils are best for health in India?
When it comes to choosing the right cooking oil, variety and moderation are key. According to Dr Dua, these are:
Healthier oils to include:
Mustard oil – Rich in omega-3s and monounsaturated fats, heart-friendly
Groundnut (peanut) oil – High in MUFAs, ideal for Indian cooking
Olive oil – Anti-inflammatory, great for salads and light cooking
Sesame oil – A balance of MUFAs and PUFAs, suitable for stir-frying
Rice bran oil – Contains oryzanol, which helps reduce cholesterol
Flaxseed oil – High in omega-3s, best for cold preparations
Oils to limit or avoid:
Refined oils (e.g. refined sunflower, soybean) – Stripped of nutrients
Palm oil, coconut oil – High in saturated fats
Partially hydrogenated oils – Major source of trans fats, harmful for heart health
'Cold-pressed oils are always a better choice. They retain antioxidants and beneficial compounds lost in the refining process,' Dr Dua advises.
Health risks of excess oil in your diet
According to Dr Dua, excess oil intake doesn't just add calories—it directly affects long-term health. Key risks include:
Cardiovascular diseases – Saturated and trans fats raise LDL (bad cholesterol)
Obesity and diabetes – Excess calories from oil contribute to weight gain and insulin resistance
Cancer risk – High intake of unhealthy fats linked to breast, colon, and prostate cancers
Inflammation – Overconsumption of omega-6 oils may promote chronic inflammation
'Most people track their rotis and rice but not the 2–3 extra tablespoons of oil in everyday cooking. That's where the problem begins,' she notes.
How to use cooking oil safely: Portion control and smart swaps
Instead of cutting out oil entirely, focus on:
Quantity control – 3–4 teaspoons (15–20 ml) of oil per day is sufficient for a sedentary adult
Label check – Look for oils with MUFA/PUFA; avoid hydrogenated or refined oils in excess
Smart cooking – Prefer boiling, steaming, grilling over deep-frying
Oil rotation – Mix oils (e.g. mustard and groundnut) to get a balance of fatty acids
Is reusing cooking oil dangerous? Yes—here's why
Reheating or reusing oil—especially after deep frying—creates toxic compounds like acrolein and aldehydes, which can damage organs over time.
How to calculate daily oil intake for your family
Dr Dua recommends a simple formula:
'Track your household's monthly oil usage. Divide it by the number of members. Ideally, each person shouldn't exceed 500 ml per month—that's roughly 3–4 teaspoons per day.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
29 minutes ago
- Economic Times
KKR-backed IVI to buy ART Fertility Clinics for $450 million
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.


Time of India
an hour ago
- Time of India
Seminar on MBBS, global education pathways in Pune draws enthusiastic response
1 2 P une: A large gathering of aspiring students and parents attended an informative Mission Admission seminar organised by The Times of India jointly with The Astute Academy at Dr. Kalmadi Shamarao Junior College auditorium on Sunday. Conducted by Tushar Vinod Deoras, a former BARC scientist and chairman of Astute Academy, the seminar aimed to demystify the complexities of Indian and international admissions for MBBS and higher education. The first session focused on the Indian MBBS admission process, offering clarity for students with NEET scores as low as 200. Attendees also learned about affordable pathways to study medicine in the United States through structured Indo-American university collaborations. The second session delved into undergraduate and postgraduate admissions in the US and Germany. Parents and students were provided with detailed guidance on securing spots at prestigious universities abroad. During the first session, Deoras shared a wealth of information. He pointed out that many private medical colleges offer donation-free management quota merit seats. He explained fee structures, wherein funding is controlled by govt, and proposed to students tripartite Indo-American university partnered systems, which provide affordable, sophisticated modern medical education in the US and subsequently offer employer-relevant value around the globe. The second session was about undergraduate and postgraduate courses offered in the US and Germany, particularly emphasising on Ivy League schools and Germany's technical universities. Deoras noted how flexible and multidisciplinary the US system is, with more emphasis on career focus than rigid course structures. He urged students to start building their profiles as early as Std IX and to apply to international universities at least one year in advance, as most operate on a first-come, first-served basis. He said, "Quality education and a successful career are a student's fundamental right. Students and parents should not judge countries by stereotypes but understand which system aligns best with the student's goals." A highlight of the seminar was its interactive nature. One parent shared, "The session was very enlightening. Many doubts regarding my son's education were resolved, and I feel much more at peace now." Another participant raised a query about dentistry as a career path, to which Deoras responded that it remains an underappreciated but highly rewarding field in India. While initial years in practice may be challenging, dentistry offers significant long-term growth and financial prospects. Deoras also addressed several audience questions about state-wise admission quotas for MBBS, the application process for foreign universities, and the admission timelines and requirements for medical education abroad. The seminar concluded with a positive response from the audience who appreciated the transparency, practical guidance, and motivational approach.


Time of India
an hour ago
- Time of India
KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin America. Both parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June end. As with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) valuation. ART Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and India. Live Events With clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Capital. ART Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and Faridabad. Led by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine years. According to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million. "For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well." IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals. A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to queries. Moelis is the advisor in the transaction. India is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in Europe. Infertility affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and pollution. According to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%. India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall Clinic. Nova IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and TPG. Similarly, homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.